Culture-Free Rapid Phenotypic Antimicrobial Susceptibility Testing for Helicobacter pylori Based on Fluorescence Rapid On-Site Evaluation Technology: A Preliminary Study

Technical Summary: Culture-Free Rapid Phenotypic AST for H. pylori via ROSE Technology

Problem Statement
Current phenotypic antimicrobial susceptibility testing (AST) for Helicobacter pylori has been constrained for three decades by the requirement for bacterial culture, a process that necessitates 5–7 days to yield results. While genotypic rapid tests exist, they are limited to detecting known resistance mutations and fail to reliably identify resistance to amoxicillin, a critical first-line antibiotic lacking a reliable genetic resistance marker. Consequently, there is a significant unmet clinical need for a culture-free, rapid phenotypic AST method capable of guiding same-day treatment decisions.

Methodology
This study introduces a novel phenotypic AST method utilizing Fluorescence Rapid On-Site Evaluation (ROSE) technology, designed to bypass bacterial culture entirely. The protocol involved the following steps:

• Sample Preparation: Gastric mucosal biopsy specimens from 40 H. pylori-positive patients were homogenized.
• Incubation: Samples were co-incubated for 1 hour at 37°C with an acridine orange/ethidium bromide (AO/EB) viability staining reagent and three first-line antibiotics: amoxicillin, clarithromycin, and levofloxacin.
• Concentration Standards: Antibiotic concentrations were set according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for H. pylori.
• Detection: Fluorescence intensity was measured using a microplate reader. The principle relies on viability staining: a reduction in fluorescence relative to an antibiotic-free control indicates bacterial susceptibility (growth inhibition), while no significant reduction indicates resistance.
• Reference Standard: Conventional culture-based AST (E-test) served as the reference method for validation.

Key Contributions

• First Culture-Free Phenotypic AST: This study reports the first instance of a culture-free, 1-hour phenotypic AST method specifically for H. pylori.
• Amoxicillin Susceptibility Assessment: Unlike genotypic methods, the ROSE approach successfully assessed amoxicillin susceptibility in all patients, addressing a critical gap where no reliable genetic resistance marker currently exists.
• Operational Efficiency: The method reduces the turnaround time from 5–7 days to approximately 1 hour (55–65 minutes).
• Cost Reduction: Preliminary estimates suggest a cost reduction of approximately 3,000–5,000 Chinese yuan (CNY) per patient, driven by the elimination of culture media, prolonged incubation periods, and the need for repeat clinic visits.

Results
From the initial 40 samples, 14 were excluded due to unsuccessful culture, leaving 26 samples for statistical analysis against the reference method:

• Concordance Rates: The overall concordance between the ROSE method and culture-based AST was 84.6% (22/26) for amoxicillin, 76.9% (20/26) for levofloxacin, and 69.2% (18/26) for clarithromycin.
• Statistical Agreement: Cohen's kappa coefficients indicated moderate agreement for all three antibiotics, with values of 0.523 (amoxicillin), 0.539 (levofloxacin), and 0.412 (clarithromycin).
• Feasibility: The method demonstrated the ability to provide susceptibility data within an hour, enabling potential same-day treatment decisions.

Significance and Future Directions
The authors posit that this study addresses a clinical need spanning three decades by enabling susceptibility-guided treatment decisions on the same day. While the preliminary results are promising, the paper maintains a modest stance regarding immediate clinical deployment. The authors state that algorithm optimization and a prospective randomized controlled trial are currently underway to further improve diagnostic accuracy and validate clinical utility before broader implementation.